A Ramp Up In Keytruda Sales Will Likely Drive Merck's Q2 Earnings Growth

Merck (NYSE:MRK) is set to report its Q2 2018 earnings on July 27, and we expect the company to post steady growth, primarily led by its Oncology drug Keytruda. Among other segments, Anti-Infectives will likely remain sluggish, due to competitive pressure for Zepatier. Within Vaccines...